LLY
A tiny infusion, a big cholesterol flex
Lilly just dropped early-stage data for VERVE-102, its investigational in vivo base-editing drug aimed at turning down the PCSK9 gene in the liver. In the Phase 1b Heart-2 trial, a single intravenous infusion led to dose-dependent reductions in PCSK9 and LDL-C, with the biggest cuts hitting up to 88% for PCSK9 and 62% for LDL-C.
Why investors should care
This is the kind of biotech headline that makes you pause mid-scroll. The big promise here is durability: Lilly says the effects lasted as long as 18 months in follow-up, which is the holy grail for chronic disease treatment. Instead of a daily pill or frequent injection, the pitch is a one-time treatment for people with heterozygous familial hypercholesterolemia or premature coronary artery disease.
The long game is the real story
VERVE-102 is designed to mimic naturally occurring loss-of-function variants in PCSK9 — basically, nature’s own cheat code for lower lifetime heart-disease risk. Lilly also said it plans to start enrolling the Phase 2 study by the end of this year, so this is moving from “cool science project” territory toward something closer to a real commercial thesis.
Big picture
For Lilly, this is another reminder that it wants more than just a blockbuster obesity franchise on the shelf. If VERVE-102 keeps behaving like this, it could become one of those rare biotech shots that actually changes how you treat a massive chronic disease. For now, though, it’s still early innings — but the scoreboard looks pretty darn good.